GE HealthCare Technologies Inc. Common Stock vs Johnson Controls International PLC — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Johnson Controls International PLC trades at $152.11 (market cap $94.78B). The key difference: Johnson Controls International PLC is far larger — about 3.1× GE HealthCare Technologies Inc. Common Stock's market cap, and Johnson Controls International PLC pays the higher dividend (1.02%). Which is the better fit depends on your goals.
| GEHC | JCI | |
|---|---|---|
Market Cap | $31.07B | $94.78B |
Volume | 3,443,020 | 4,103,814 |
Sector | Health | Basic Materials |
52-Week High | $88.16 | $158.76 |
52-Week Low | $59.48 | $108.54 |
Enterprise Value | $39.53B | $103.61B |
Dividend Yield | 0.23% | 1.02% |
Typical Hold Time | — | 66 Days |
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Johnson Controls International (JCI) trades at $152.44, down 1.91% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $1.42 beating estimates of $1.30, maintaining a three-quarter beat streak. Revenue trends show recovery from $23.0B in 2024 to $23.6B in 2025, with net income margin expanding significantly to 13.94%. Recent news highlights strong Q3 2026 results with 10% organic sales growth and raised full-year guidance.
JCI presents a compelling investment case with analyst consensus strongly bullish (62% buy ratings) and a $172.50 price target offering 13% upside. Key opportunities include strong demand for data-center thermal management systems and expanding profit margins. Risks include elevated valuation multiples (P/E 44.08) and increasing debt-to-asset ratio (26.06% in 2025). The stock's technical position near key support at $153 requires monitoring for sustained bullish momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →